JAMA Network
About The Study: In this large cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a modestly increased risk of nonarteritic anterior ischemic optic neuropathy compared with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
